IDNA vs VHT

Key Takeaways

• IDNA is a thematic ETF targeting genomics, immunology, and bioengineering companies, while VHT provides broad exposure across the entire U.S. health care sector.
• IDNA typically holds 50-65 securities with heavy concentration in biotechnology, whereas VHT maintains over 400 holdings diversified across pharmaceuticals, biotechnology, medical equipment, and health care services.
• IDNA carries a higher expense ratio of 0.47% compared to VHT's 0.09%, reflecting its specialized thematic strategy versus VHT's low-cost passive approach.
• IDNA exhibits greater volatility and higher sensitivity to biotech innovation cycles and regulatory developments in gene therapies, while VHT offers more stable performance tied to broader health care demand and established large-cap companies.
• Both ETFs are passively managed and focus exclusively on health care, yet they differ significantly in diversification, geographic scope, and risk exposure within the sector.
• IDNA emphasizes emerging therapeutic technologies globally, positioning it for long-term growth in precision medicine, whereas VHT prioritizes established U.S. health care leaders for consistent sector representation.

Introduction

Investors seeking health care exposure often evaluate thematic and broad-sector ETFs to align with specific objectives. The iShares Genomics Immunology and Healthcare ETF (IDNA) and the Vanguard Health Care ETF (VHT) both target the health care sector but pursue distinct strategies. IDNA concentrates on companies advancing genomics, immunology, and bioengineering, offering targeted access to innovation-driven segments. VHT delivers diversified exposure across the full U.S. health care industry through a market-cap-weighted index. These ETFs do not compete directly but serve as complementary or alternative options depending on an investor's preference for thematic concentration versus broad sector stability. Comparing their structures highlights differences in cost, holdings, and positioning amid ongoing advancements in biotechnology and health care delivery.

iShares Genomics Immunology and Healthcare ETF (IDNA) Overview

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index, focusing on global companies positioned to benefit from long-term growth in genomics, immunology, and bioengineering. The fund holds approximately 50 to 65 securities, with a strong emphasis on biotechnology firms. Top holdings frequently include Moderna (MRNA), Twist Bioscience (TWST), Iovance Biotherapeutics (IOVA), Genmab, and Revolution Medicines (RVMD). Sector allocation centers almost entirely on health care, particularly biotechnology and related sub-industries. IDNA maintains an expense ratio of 0.47% and operates as a passively managed thematic ETF. Its global scope includes developed and select emerging markets, with rebalancing aligned to the underlying index methodology. This structure suits investors seeking concentrated exposure to cutting-edge therapeutic platforms rather than broad health care representation.

Vanguard Health Care ETF (VHT) Overview

The Vanguard Health Care ETF (VHT) tracks the MSCI US Investable Market Health Care 25/50 Index, providing exposure to large-, mid-, and small-cap U.S. companies classified within the health care sector under the Global Industry Classification Standard (GICS). The fund typically holds more than 400 securities, spanning pharmaceuticals, biotechnology, health care equipment, life sciences tools, managed care, and services. Prominent holdings often feature Eli Lilly (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck (MRK), and UnitedHealth Group (UNH). Sector weights emphasize pharmaceuticals and biotechnology while including meaningful allocations to equipment and services. VHT features a low expense ratio of 0.09% and follows a passive, market-cap-weighted approach with periodic index rebalancing. Its U.S.-centric focus and broad diversification make it a core holding for investors seeking comprehensive health care sector exposure with lower costs and reduced single-stock concentration.

Industry and Thematic Backdrop

The health care sector continues to benefit from structural tailwinds including aging populations, rising chronic disease prevalence, and accelerating innovation in precision medicine and biologics. Regulatory environments in major markets support accelerated approvals for novel therapies, while capital flows into biotechnology research remain robust. Macroeconomic factors such as interest rate trajectories influence funding availability for early-stage companies, and geopolitical developments can affect global supply chains for pharmaceuticals and medical devices. Risks include pricing pressures, reimbursement uncertainties, and potential policy shifts regarding drug affordability. Both ETFs operate within this dynamic landscape, where thematic innovation in genomics intersects with established health care demand drivers, creating varied opportunities across sub-sectors.

Performance and Positioning Comparison

In recent market cycles, IDNA has demonstrated higher volatility consistent with its concentrated biotechnology focus, often exhibiting stronger responsiveness to breakthroughs in gene and cell therapies as well as earnings developments among smaller innovative firms. VHT has delivered more measured returns aligned with the broader health care sector, benefiting from stable contributions by large pharmaceutical and managed care companies during periods of sector rotation. Relative positioning reflects differing sensitivities: IDNA tends to amplify gains or losses tied to biotech-specific catalysts and interest rate expectations affecting growth stocks, while VHT provides steadier participation in overall health care utilization trends and defensive characteristics during economic uncertainty. These dynamics underscore IDNA's role as a higher-risk complement and VHT's function as a diversified core allocation within health care portfolios.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore tailored insights for ETFs like IDNA and VHT.

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would likely favor the Vanguard Health Care ETF (VHT) in the current environment. Its significantly lower expense ratio, extensive diversification across hundreds of holdings, and broad representation of established health care leaders provide greater cost efficiency and reduced idiosyncratic risk compared to the more concentrated and higher-cost iShares Genomics Immunology and Healthcare ETF (IDNA). While IDNA offers compelling thematic exposure to genomics innovation, VHT's profile aligns better with consistent sector momentum and lower volatility across market cycles, supporting a probabilistic preference for broader positioning at this time.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations